ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

AMRN Amarin Corp PLC

0.9289
0.0519 (5.92%)
30 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Amarin Corp PLC AMRN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.0519 5.92% 0.9289 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.884 0.8692 0.9289 0.9209 0.877
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202413:00GLOBEAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA..
22/4/202407:00GLOBEAmarin Announces Results of Annual General Meeting of..
15/4/202407:00GLOBEAmarin to Report First Quarter 2024 Financial Results and..
08/4/202407:00GLOBEAmarin Highlights Key Data Providing Mechanistic Insights..
08/4/202405:30PRNCANew REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl)..
06/4/202414:30GLOBENew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent..
03/4/202407:00GLOBEAmarin Provides Update on VAZKEPA® (Icosapent Ethyl)..
25/3/202407:00GLOBEResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent..
04/3/202416:30EDGAR2Form ARS - Annual Report to Security Holders
04/3/202407:00EDGAR2Form DEF 14A - Other definitive proxy statements
29/2/202406:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202406:05EDGAR2Form 8-K - Current report
29/2/202406:00GLOBEAmarin Reports Fourth Quarter and Full Year 2023 Financial..
15/2/202407:00GLOBEAmarin to Report Fourth Quarter and Full Year 2023 Financial..
12/2/202407:00EDGAR2Form PRE 14A - Other preliminary proxy statements
09/2/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202406:00EDGAR2Form 8-K - Current report
24/1/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202406:30GLOBEAmarin Chairman & CEO Issue Letter to Shareholders
12/1/202416:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202416:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202416:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202406:00EDGAR2Form 8-K - Current report
10/1/202406:00GLOBEAmarin Provides Preliminary Fourth Quarter 2023 Selected..
08/1/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202317:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:20EDGAR2Form 144 - Report of proposed sale of securities
11/12/202307:00GLOBEAmarin to Present at the 42nd Annual J.P. Morgan Healthcare..
05/12/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202306:30EDGAR2Form SC 13D/A - General statement of acquisition of..
12/11/202308:00GLOBENew REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl)..
03/11/202315:30EDGAR2Form 8-K - Current report
01/11/202306:05EDGAR2Form 8-K - Current report
01/11/202306:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202306:00GLOBEAmarin Reports Third Quarter 2023 Financial Results
31/10/202315:05EDGAR2Form 8-K - Current report
31/10/202311:00GLOBEAmarin Appoints Jonathan Provoost Executive Vice President,..
26/10/202307:00GLOBELatest Research Evaluating VASCEPA®/VAZKEPA® (icosapent..
19/10/202307:00GLOBE Amarin to Report Third Quarter 2023 Financial Results and..
12/9/202307:00GLOBEAmarin to Present at the 2023 Cantor Global Healthcare..
05/9/202315:15EDGAR2Form SC 13D/A - General statement of acquisition of..
16/8/202318:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

Delayed Upgrade Clock